Andere talen AtriCure, Inc.

Aandelen

ATRC

US04963C2098

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
23,39 ^USD	-0,26%		-7,59%	-34,46%

18/04	AtriCure, Inc. Kondigt de lancering aan van de CryoSPHERE®?+ sonde voor postoperatieve pijnbestrijding	CI
07/03	AtriCure Insider verkocht aandelen ter waarde van $307.510, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management	18/04
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	18/04
AtriCure to Announce First Quarter 2024 Financial Results	10/04
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference	26/03
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	07/03
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	27/02
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	15/02
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	15/02
AtriCure: Q4 Earnings Snapshot	15/02
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results	15/02
Atricure, Inc. Provides Earnings Guidance for 2024	15/02
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference	25/01
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise	08/01
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024	08/01
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement	08/01
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024	08/01
AtriCure Appoints Shlomi Nachman to the Board of Directors	04/01
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors	04/01
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen AtriCure, Inc.

Aandelen

ATRC

US04963C2098

Andere talen

Filters